Kamal Desai
Research Subjects
Kamal Desai has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Maguire
Health Economics and Epidemiology, Evidera, Metro Building, 6th floor, No.1 Butterwick, London W6 8DL, UK
1 shared publication - Dominic Muston
Bayer US LLC, Whippany, New Jersey, United States
1 shared publication - Javaria Mona Khalid
Health Economics and Epidemiology, Evidera, Metro Building, 6th floor, No.1 Butterwick, London W6 8DL, UK
1 shared publication - Javier Cid-Ruzafa
Evidera, 08005 Barcelona, Spain
1 shared publication - Justyna M Starczewska Amelio
Health Economics and Epidemiology, Evidera, Metro Building, 6th floor, No.1 Butterwick, London W6 8DL, UK
1 shared publication - Philip Ashman
Health Economics, Bayer plc, Strawberry Hill, Newbury RG14 1JA, UK
1 shared publication
Latest Publications
- Open Access
- 24 May 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 364
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model
The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an ultra-orphan disease threshold of 2/100,000 population used in England and Wales. Our study was designed to estimate the prevalence and absolute number of UK patients with unresectable/metastatic GIST at first-, second- and eventually third-line treatment.
- 24 May 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 364
Open AccessPrevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model
The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an ultra-orphan disease threshold of 2/100,000 population used in England and Wales. Our study was designed to estimate the prevalence and absolute number of UK patients with unresectable/metastatic GIST at first-, second- and eventually third-line treatment.